Drug intelligence / Profile preview

abatacept + etanercept

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

A combination of two biologic disease-modifying antirheumatic drugs (DMARDs) used for treating autoimmune conditions. Abatacept is a selective T-cell costimulation modulator that inhibits T-cell activation by binding to CD80 and CD86 receptors. Etanercept is a TNF inhibitor that binds to tumor necrosis factor and blocks its interaction with cell surface TNF receptors.

Targets

TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)

Beyond the preview

Go deeper on abatacept + etanercept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abatacept + etanercept.

Explore the full profile